Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine
作者机构：Department of BiotechnologyMotilal Nehru National Institute of TechnologyAllahabadUP211004India
出 版 物：《Genes & Diseases》 (基因与疾病（英文）)
年 卷 期：2021年第8卷第2期
页 面：133-145页
核心收录：
学科分类：0710[理学-生物学] 0831[工学-生物医学工程（可授工学、理学、医学学位）] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 0703[理学-化学] 10[医学]
基 金：The study is supported by Department of Biotechnology grant no.6242-P103/RGCB/PMD/DBT/SMSV/2015.Authors are thankful to the Ministry of Human Resource and Development and CSIR Govt.of India New Delhi India for providing scholarship during this tenure.The authors acknowledge Dr.Tonima Kamat for critically reviewing the manuscript.
主 题：Biomarkers CMS subtypes Immunotherapy Molecular screening Personalized medicine
摘 要：Molecular subtypes-based therapies offer new potential framework for desired and precise outcome in clinical settings.Current treatment strategies in colorectal cancer are largely‘one drug fit all’model for patients that display same pathological conditions.However,CRC is a very heterogenous set ofmalignancy that does not support for above criteria.Each subtype displays different pathological and genetic signatures.Based on these features,therapeutic stratification for individual patients may be designed,which may ultimately lead to improved therapeutic outcomes.In this comprehensive review,we have attempted to briefly outline major CRC pathways.A detailed overview of molecular subtypes and their clinical significance has been discussed.Present and futuremethods,governing CRC subtyping in the era of personalized therapywith a special emphasis on CMS subtypes of CRC has been reviewed.Together,discovery and validation of new CRC patient stratification methods,screening for novel therapeutic targets,and enhanced diagnosis of CRC may improve the treatment outcome.
维普期刊数据库